Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVACFLU refers to a series of influenza vaccines developed and manufactured by the Institute of Vaccines and Medical Biologicals (IVAC) in Vietnam. These vaccines are designed to prevent influenza infection by stimulating an immune response against specific influenza virus strains. The product line includes an inactivated whole cell vaccine for Influenza A/H5N1 (IVACFLU-A/H5N1), which is alum-adjuvanted, and seasonal trivalent inactivated split virion vaccines (IVACFLU-S) that target common influenza strains such as A/H1N1, A/H3N2, and B. The vaccines are produced using embryonated chicken eggs and are inactivated with formaldehyde. Clinical trials have demonstrated their safety and immunogenicity in healthy adults and other age groups.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IVACFLU.